Last week, the American Society of Hematology (ASH) released abstracts for the upcoming 58th Annual Meeting & Exposition to be held December 3-6, 2016 in San Diego, CA. Included as part of the release was abstract #4050 from Actinium Pharmaceuticals, Inc. (NYSEMKT: ATNM). The abstract highlights the company’s Phase 1 clinical results with Actimab-A for the…
Valeritas Holdings, Inc. (VLRX) is a commercial-stage medical device company focused on developing innovative technologies to improve the health and quality of life for people with Type 2 diabetes. The company’s flagship product is called V-Go, and it is currently on the market in the U.S. V-Go is a small, wearable device designed for patients…
I’ve been following VistaGen Therapeutics (NASDAQ: VTGN) for several months now. The California-based biotech is developing AV101, a glycine B (GlyB) receptor antagonist that negatively modulates the N-Methyl-D-aspartic acid (NMDA) receptor. AV-101 is an oral prodrug candidate that has demonstrated impressive antidepressant effects and safety in preclinical and Phase 1 studies. The mechanism of action…
Last month, Actinium Pharmaceuticals Inc. (NYSEMKT: ATNM) announced the initiation of a Phase 2 clinical trial of Actimab-A in patients newly diagnosed with Acute Myeloid Leukemia (AML) who are over the age of 60. Elderly patients with AML face poor prognosis and have limited viable treatment options. it is an area of significant unmet medical…
Relmada Therapeutics (OTC: RLMD) is developing REL-1017 for the treatment of depression and neuropathic pain. REL-1017, also known as dextromethadone or d-methadone, is a non-competitive antagonist of the N-methyl-D-aspartic acid (NMDA) receptor. This mechanism of action has received significant attention from the psychiatric community over the past several years due to the expected rapid onset…
On September 19, 2016, MabVax Therapeutics, Inc (NASDAQ: MBVX) provided a brief update on the ongoing Phase 1 clinical trial testing the safety and tolerability of MVT-5873 as a monotherapy and with chemotherapy in subjects with advanced prostate cancer. MVT-5873 is the company’s fully human monoclonal antibody, HuMab-5B1, that targets the tetrasaccharide carbohydrate moiety sLeA…
In July 2016, BrainStorm Cell Therapeutics (NASDAQ: BCLI) reported top-line data from a Phase 2 multi-center study with NurOwn® for the treatment of ALS. The company is currently in the process of finalizing the full data analysis from this trial and plans to submit the results for presentation at a medical conference during the first…
Actinium Pharmaceuticals (NYSEMTK: ATNM) is a biopharmaceutical company developing targeted radioimmunotherapies for the treatment of cancer. The company has two clinical-stage programs, Iomab-B and Actimab-A. Iomab-B was licensed from the Fred Hutchinson Cancer Research Cancer and is currently in a pivotal Phase 3 clinical trial investigating the use as an induction and conditioning agent prior…
As many investors know, I’ve written extensively on RedHill Biopharma Ltd. (NASDAQ: RDHL) over the past year. My article in August 2016 (LINK) is a good synopsis for many of my past more detailed works. In that article, I noted the company has, “One of the deepest and most interesting pipelines in specialty pharma.” I…
MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX) is a biopharmaceutical company developing monoclonal antibody (mAb) products for the treatment of cancer. The company’s novel mAb technology involves a unique twist on the generation of fully human mAbs as they are derived from patients vaccinated with an anti-cancer vaccine, as opposed to antibodies produced in mice or…